Chuanbing Zang
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism 3
- Cancer, Lipids, and Metabolism 3
- Hematology top 10%
- Chronic Myeloid Leukemia Treatments 4
- Genetics top 10%
- Chronic Lymphocytic Leukemia Research 3
- Rehabilitation top 10%
- Oncology top 10%
-
- Peroxisome Proliferator-Activated Receptors 10
- Retinoids in leukemia and cellular processes 6
- PI3K/AKT/mTOR signaling in cancer 5
- Ubiquitin and proteasome pathways 4
- Co-authors
- Kurt PossingerJan EuckerElena ElstnerHongyu LiuChristian SchölzCarsten‐Oliver SchulzChristian RiesManfred G. Ismair
- Cited by
- Cancer ResearchHematologyGenetics
- Journals
- Proceedings of the National Academy of Sciences (1 paper)Blood (1 paper)Cancer Research (1 paper)
- Partner nations
- GermanyUnited StatesChina
In The Last Decade
Chuanbing Zang
31 papers receiving 897 citations
Peers
Comparison fields: 5 of 78
- Cancer Research 233
- Hematology 140
- Genetics 107
- Rehabilitation 68
- Oncology 250
Countries citing papers authored by Chuanbing Zang
This map shows the geographic impact of Chuanbing Zang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chuanbing Zang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chuanbing Zang more than expected).
Fields of papers citing papers by Chuanbing Zang
This network shows the impact of papers produced by Chuanbing Zang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chuanbing Zang. The network helps show where Chuanbing Zang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Chuanbing Zang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 5 | |
| 2 | 2023 | 2 | |
| 3 | 2022 | 22 | |
| 4 | 2021 | 13 | |
| 5 | 2018 | 12 | |
| 6 | 2016 | 1 | |
| 7 | TKI258, a multi-tyrosine kinase inhibitor is efficacious against human infant/childhood lymphoblastic leukemia in vitro. | 2014 | 4 |
| 8 | 2013 | 40 | |
| 9 | 2013 | 35 | |
| 10 | 2012 | 32 | |
| 11 | 2009 | 9 | |
| 12 | 2008 | 107 | |
| 13 | 2006 | 19 | |
| 14 | 2006 | 28 | |
| 15 | 2006 | 57 | |
| 16 | 2004 | 34 | |
| 17 | Somatic mutations in peroxisome proliferator-activated receptor-gamma are rare events in human cancer cells. | 2004 | 19 |
| 18 | 2003 | 36 | |
| 19 | 2003 | 53 | |
| 20 | 2000 | 32 |
About Chuanbing Zang
Chuanbing Zang is a scholar working on Cancer Research, Hematology and Molecular Biology, having authored 31 papers that have together received 907 indexed citations. Recurring topics across this work include Peroxisome Proliferator-Activated Receptors (10 papers), Retinoids in leukemia and cellular processes (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Chronic Myeloid Leukemia Treatments (4 papers), Ubiquitin and proteasome pathways (4 papers), Chronic Lymphocytic Leukemia Research (3 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer, Lipids, and Metabolism (3 papers). The work is most often cited by research in Cancer Research (233 citations), Hematology (140 citations) and Genetics (107 citations). Chuanbing Zang has collaborated with scholars based in Germany, United States and China. Frequent co-authors include Kurt Possinger, Jan Eucker, Elena Elstner, Hongyu Liu, Hongyu Liu, Christian Schölz, Carsten‐Oliver Schulz, Christian Ries, Manfred G. Ismair and Petro E. Petrides. Their work appears in journals such as Proceedings of the National Academy of Sciences, Blood and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.